Welcome to our dedicated page for Harvard Biosci SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harvard Bioscience, Inc. (HBIO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q, 8‑K and other key documents. Harvard Bioscience is a developer, manufacturer and seller of technologies, products and services used in life science research, drug and therapy discovery, bio‑production and preclinical testing. Its filings provide detailed information on this business, its financial condition and its capital structure.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Harvard Bioscience presents audited and interim financial statements, segment and product discussions, risk factors, management’s discussion and analysis, and information on liquidity and capital resources. These filings give investors and analysts insight into revenues, margins, operating expenses, cash flows and balance sheet items, as well as commentary on trends affecting its life science tools business.
Current reports on Form 8‑K are especially important for tracking material events at Harvard Bioscience. In 2025, the company used 8‑K filings to disclose amendments to its credit agreement, a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, the issuance of warrants, Nasdaq listing and compliance notices, audit committee composition matters, retention arrangements with executives, and the announcement of quarterly financial results and conference calls. These 8‑K filings also document board appointments and CEO succession plans.
On this page, Stock Titan provides real‑time access to new HBIO filings as they appear on EDGAR, along with AI‑generated summaries that explain the core points of each document in plain language. For example, AI summaries can highlight covenant changes and going‑concern language in credit‑related filings, outline the structure of new financing arrangements, or extract key performance metrics from earnings releases furnished on Form 8‑K. Users can also review insider transaction reports on Form 4 when available, to see equity awards or share transactions by directors and officers as disclosed in SEC filings.
By consolidating Harvard Bioscience’s 10‑K, 10‑Q, 8‑K and other SEC forms with AI‑assisted analysis, this page helps readers understand how the company reports on its life science tools operations, capital structure, Nasdaq listing status and governance changes over time, without having to parse every filing manually.
Harvard Bioscience has called a virtual special stockholder meeting to vote on a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-15, plus a related proposal to allow adjournment of the meeting to solicit more proxies if needed. The Board is seeking flexibility to implement, or not implement, a single reverse split within six months after the meeting.
The company received Nasdaq deficiency notices after its share price fell below the $1.00 minimum bid requirement and has until March 30, 2026 to regain compliance. The Board views the reverse split as a potential way to increase the share price and maintain listing on The Nasdaq Capital Market, though it warns there is no assurance the price will rise or stay above $1.00 and notes possible negative effects on liquidity and trading.
Authorized shares (80,000,000 common, 5,000,000 preferred) and par value will not change, which would increase the proportion of unissued shares available for future transactions. Fractional shares will not be issued; instead, affected holders will receive cash based on the closing price before the split. As of December 31, 2025, 44,719,894 shares of common stock were outstanding, with entities affiliated with William A. Snider reported as beneficially owning 18.4%.
Harvard Bioscience, Inc. reported a corporate governance change approved by its Board of Directors on January 19, 2026. The Board adopted an amendment to the company’s Amended and Restated By-laws that lowers the quorum requirement for stockholder meetings from a majority of shares entitled to vote to one-third (1/3) of the shares entitled to vote. This change was effective immediately upon approval by the Board.
The amendment is intended to make it easier for the company to validly conduct stockholder meetings when turnout is low, since fewer shares need to be represented to reach quorum. The full text of the amendment is provided as an exhibit to the report for investors and stockholders who want to review the exact by-law language.
Harvard Bioscience, Inc. furnished an investor update slide presentation to the investment community, providing information about its business strategy and outlook. The presentation is attached as Exhibit 99.1 to this report and is being provided under Regulation FD, meaning it is intended to ensure broad, fair disclosure to all investors.
The company states that the information in the presentation is being furnished rather than filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings. The report also includes the usual caution that the presentation contains forward-looking statements based on current expectations and subject to risks and uncertainties described in the company’s most recent annual and quarterly reports.
Harvard Bioscience entered a new secured Loan and Security Agreement with BroadOak-led lenders, adding three term loans of
The loans bear interest at a minimum annual rate of
The obligations are guaranteed by certain domestic subsidiaries and secured by substantially all assets, and the agreement includes customary covenants and events of default. While the term loans remain outstanding, the administrative agent may nominate one director; in connection with this right, the board appointed William A. Snider, a BroadOak partner, to the board and its Compensation Committee, effective
Harvard Bioscience reported Q3 results showing softer demand and tighter liquidity. Revenue was $20.6 million, down 6.3% year over year, with gross margin at 58.4%. Operating income was $0.2 million, and net loss was $1.2 million (loss per share $0.03).
For the first nine months, revenue was $62.8 million (down 9.7%). A non‑cash $47.951 million goodwill impairment recorded in Q1 drove a year‑to‑date net loss of $53.9 million. Cash from operations was $6.8 million year to date, ending cash was $6.8 million, and total debt classified as current was $34.0 million.
The company disclosed substantial doubt about its ability to continue as a going concern. Lenders waived certain covenant breaches and deferred testing for Q3 under the August 2025 amendment, but the company must complete steps toward refinancing or repayment of its Credit Agreement by December 5, 2025. The amendment increased pricing to SOFR plus 700 bps and added mandatory prepayment provisions. As of November 3, 2025, common shares outstanding were 44,579,665.
Harvard Bioscience announced it issued a press release with financial results for the three and nine months ended September 30, 2025, and scheduled a conference call at 8:00 AM ET on November 6, 2025.
The release is furnished under Item 2.02 of a Form 8‑K as Exhibit 99.1 and, as furnished information, is not deemed filed under the Exchange Act.
Stephen DeNelsky, a director of Harvard Bioscience, Inc. (HBIO), reported an award of 110,000 restricted stock units on
Stephen J. DeNelsky, a director of Harvard Bioscience, Inc. (HBIO), filed an Initial Statement of Beneficial Ownership on 09/05/2025. The filing is a Form 3 and states that no securities are beneficially owned by the reporting person at the time of the report. The submission is signed by Stephen DeNelsky on 10/07/2025 and includes an Exhibit 24 power of attorney reference.
Harvard Bioscience, Inc. received notice from Nasdaq that it has been granted an additional 180 days, until March 30, 2026, to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share for continued listing. To qualify for this second compliance period, the company applied to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, and this transfer becomes effective at the opening of business on October 3, 2025.
The company originally fell out of compliance after its closing bid price stayed below $1.00 for 30 consecutive business days. If the stock closes at or above $1.00 for at least 10 consecutive business days before March 30, 2026, Nasdaq staff will confirm that the company has regained compliance. If compliance is not restored by that date, the stock will be subject to delisting, although the rules allow the company to appeal. The company plans to monitor its share price and may consider options such as a reverse stock split to regain compliance.
FAQ
What is the current stock price of Harvard Biosci (HBIO)?
What is the market cap of Harvard Biosci (HBIO)?
